Search

Displaying results 9791 - 9800 of 10000 in total
  1. Drug

    Betameprodine

    go.drugbank.com/drugs/DB01552
    ExperimentalIllicit

    Betameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances. … The stereoisomer alphameprodine is similarly classified, and was more widely used (both are referred to as Meprodine). Betameprodine is a structural analogue of meperidine.

  2. Drug

    LV-SMENP Vaccine

    go.drugbank.com/drugs/DB15804
    Experimental

    This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs). As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which

  3. Drug

    Thienylfentanyl

    go.drugbank.com/drugs/DB09180
    ExperimentalIllicit

    Thienylfentanyl is a fentanyl analog analgesic that was sold on the black market in the 1980s until the Federal Analog Act scheduled drugs based on structural similarity rather than scheduling drugs individually … Thienylfentanyl has a similar synthesis pathway to fentanyl except 2-(2-bromoethyl)thiophene is substituted for phenethyl bromide.

  4. Drug

    CHO Cells Recombinant Vaccine

    go.drugbank.com/drugs/DB15893
    Experimental

    The vaccine candidate is sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. and is undergoing phase I clinical trials to evaluate safety and tolerability. … This vaccine candidate, developed in China, uses SARS-CoV-2 protein subunits that are entirely engineered, created, and secreted by Chinese Hamster Ovary (CHO) cells[A219758].

  5. Drug

    Ingenol disoxate

    go.drugbank.com/drugs/DB15109
    Investigational

    and Extremities in Subjects With Actinic Keratosis). … Ingenol disoxate is under investigation in clinical trial NCT02120456 (Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk

  6. Drug

    PF-05241328

    go.drugbank.com/drugs/DB15124
    Investigational

    PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound

  7. Drug

    Altropane I-123

    go.drugbank.com/drugs/DB15144
    Investigational

    Altropane I-123 is under investigation in clinical trial NCT01950468 (A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the

    Synonyms: Altropane I-123
  8. Drug

    Cetuximab sarotalocan

    go.drugbank.com/drugs/DB19240
    Investigational

    Cetuximab sarotalocan is under investigation in clinical trial NCT03769506 (ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

  9. Drug

    Ancriviroc

    go.drugbank.com/drugs/DB19773
    Experimental

    Ancriviroc is a small molecule drug. The usage of the INN stem '-viroc' in the name indicates that Ancriviroc is a CCR5 (Chemokine CC motif receptor 5) receptor antagonist.

  10. Drug

    Azintuxizumab vedotin

    go.drugbank.com/drugs/DB14847
    Investigational

    Azintuxizumab vedotin is under investigation in clinical trial NCT02951117 (A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer